Lawsuits Allege GLP-1 Drugs Linked to Permanent Vision Loss

Lafayette, IN, September 22, 2026 —

Hundreds of lawsuits have been filed against pharmaceutical giants Eli Lilly and Novo Nordisk, with plaintiffs alleging that their widely prescribed GLP-1 drugs have led to permanent vision loss. The medications in question include popular brands such as Ozempic, Wegovy, and Mounjaro.

The core of the legal claims centers on a condition known as non-arteritic anterior ischemic optic neuropathy (NAION). Plaintiffs in these suits assert that these GLP-1 drugs caused or contributed to the development of NAION, a serious condition that can result in irreversible damage to the optic nerve and subsequent vision impairment.

A significant point of contention in the litigation is the alleged failure of the drug manufacturers to adequately warn patients and healthcare providers about this specific risk associated with their medications. Plaintiffs claim they were not sufficiently informed about the potential for NAION and the associated permanent vision loss before or during their treatment.

Both Eli Lilly and Novo Nordisk have responded to the allegations. The companies reportedly deny a significant causal link between their GLP-1 drugs and the development of NAION. They maintain that their medications are safe and effective when used as prescribed and that they have provided appropriate information regarding potential side effects.

The number of lawsuits filed indicates a growing concern among patients and legal representatives regarding the ocular safety profile of these increasingly popular diabetes and weight-loss medications. The litigation is ongoing, with further developments expected as cases progress through the legal system. The specific details of the plaintiffs’ alleged injuries and the companies’ defense strategies are central to the proceedings.

Story summarized from the original created by Emily Van de Riet on www.wlfi.com, see more information here.

Media gallery